StockTipsArenaBeta

SELL Cipla Ltd. — Morgan Stanley

SELLCipla Ltd.
Cipla share price target & all analyst calls

byMorgan StanleyHorizon: NA (inferred 1 year)28 Oct 2026via ET Now (Live)

Entry₹1,335.2Inferred
Target₹1,214
Total upside +9.08%
Stop lossNot given
CMP₹1,365.66h ago
Active-2.28%+11.10%upside left 12 mo left
Follow Morgan Stanley for new calls(97% target hit, 33 closed calls)Get alertsWatch CIPLA for new buy/sell callsGet alertsSee 18 other Long-term calls on CIPLASee 200 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

As of 28 Oct, 10:32 pm IST
13 supporting13 neutral13 opposing
Supports the SELL call (13)

Long-term trend bearish — 200-day average falling over the past quarter

Technicals · trend·28 Oct · today

Cipla Eyes Margin Rebound From FY28 As Middle East Freight Squeeze Hits Q2 Costs

NewsNdtv-Profit·27 Oct · yesterday

(opens in new tab)

Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%

NewsEt-Markets·27 Oct · yesterday

(opens in new tab)

Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%

NewsEt-Markets·27 Oct · yesterday

(opens in new tab)

Cipla Q2 Preview: Net Profit Seen Falling 29% As US Business Faces Headwinds

NewsNdtv-Profit·26 Oct · 2d ago

(opens in new tab)
Neutral / worth noting (13)

Cipla Q2 Results: US sales meet expectations, margins narrow from last year

NewsCnbc-Tv18·27 Oct · yesterday

(opens in new tab)

Cipla Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·27 Oct · yesterday

(opens in new tab)

These four pharma stocks will be reacting to important news updates today

NewsCnbc-Tv18·5 Oct · 3w ago

(opens in new tab)
Weighs against the SELL call (13)

Cipla Q2 Results Review: ICICI Securities Remains Bullish After Inline Numbers; Check Target Price

NewsNdtv-Profit·28 Oct · today

(opens in new tab)

Cipla’s US recovery, biosimilar pipeline key to future growth prospects

NewsEt-Markets·28 Oct · today

(opens in new tab)

9 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·28 Oct · today

Dr Reddy's stock could rise 10-15% if a major biosimilar gets approved in December: Systematix

NewsCnbc-Tv18·27 Oct · yesterday

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Cipla

All analyst calls on Cipla

More from Morgan Stanley

Every call and its outcome